Wilmington Savings Fund Society FSB Decreases Stock Position in Amgen Inc. $AMGN

Wilmington Savings Fund Society FSB decreased its position in Amgen Inc. (NASDAQ:AMGN) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,377 shares of the medical research company’s stock after selling 1,826 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Amgen were worth $15,627,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in AMGN. Legacy Investment Solutions LLC purchased a new stake in Amgen during the 2nd quarter worth $27,000. Evelyn Partners Investment Management LLP acquired a new stake in Amgen during the 2nd quarter valued at approximately $32,000. Howard Hughes Medical Institute acquired a new stake in Amgen during the 2nd quarter valued at approximately $32,000. Quaker Wealth Management LLC increased its holdings in Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after purchasing an additional 240 shares during the last quarter. Finally, Nvwm LLC grew its position in shares of Amgen by 893.3% during the second quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock worth $42,000 after buying an additional 134 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Royal Bank Of Canada upped their price target on shares of Amgen from $330.00 to $335.00 and gave the company an “outperform” rating in a report on Thursday, January 8th. Truist Financial upped their target price on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Daiwa Capital Markets boosted their price objective on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Wall Street Zen upgraded Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, December 15th. Finally, Erste Group Bank raised Amgen from a “hold” rating to a “buy” rating in a report on Friday, December 5th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $339.45.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $330.03 on Friday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The firm has a market capitalization of $177.71 billion, a PE ratio of 25.50, a P/E/G ratio of 2.93 and a beta of 0.45. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $346.38. The business’s fifty day moving average price is $331.36 and its two-hundred day moving average price is $305.66.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.1%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio is presently 73.57%.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.76% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.